Method for refolding insoluble aggregates of hepatitis C virus protease
    2.
    发明授权
    Method for refolding insoluble aggregates of hepatitis C virus protease 失效
    重新折叠丙型肝炎病毒蛋白酶不溶性聚集体的方法

    公开(公告)号:US5714371A

    公开(公告)日:1998-02-03

    申请号:US571643

    申请日:1995-12-13

    摘要: A method for solubulizing and refolding insoluble aggregates of HCV protease is presented. Insoluble aggregates of HCV NS3 protease are extracted from bacteria producing the aggregates. The aggregates of HCV NS3 are then solubilized in a buffer containing the denaturing reagent. Solubilized protease is then placed in an acidic buffer containing a reducing agent. The denaturing reagent is then removed from the buffer under acidic conditions. The pH of the buffer containing HCV NS3 protease is then raised in a step-wise manner to a pH of about 7-8 so as to produce properly refolded soluble, active HCV NS3 protease.

    摘要翻译: 提出了一种用于溶解和重折叠HCV蛋白酶不溶性聚集体的方法。 从产生聚集体的细菌中提取HCV NS3蛋白酶的不溶性聚集体。 然后将HCV NS3的聚集体溶解在含有变性试剂的缓冲液中。 然后将溶解的蛋白酶置于含有还原剂的酸性缓冲液中。 然后在酸性条件下从缓冲液中除去变性试剂。 然后将含有HCV NS3蛋白酶的缓冲液的pH逐步升高至约7-8的pH,以产生适当重折叠的可溶性活性HCV NS3蛋白酶。

    Polypeptide inhibitors of gamma interferon
    6.
    发明授权
    Polypeptide inhibitors of gamma interferon 失效
    γ干扰素的多肽抑制剂

    公开(公告)号:US5632988A

    公开(公告)日:1997-05-27

    申请号:US859292

    申请日:1992-04-07

    摘要: Novel synthetic polypeptides comprising the amino acid subsequence Arg-Arg-Lys-Trp-Gln are provided by this invention. Also provided are methods for the use of such polypeptides, other known polypeptides containing such subsequence and a variety of acidic or basic polypeptides and proteins as inhibitors of the binding of gamma interferon to its cellular receptors. The methods of this invention are potentially applicable to the treatment of pathological conditions believed to be mediated by gamma interferon, such as autoimmune disease.

    摘要翻译: PCT No.PCT / US90 / 05908 Sec。 371日期:1992年4月7日 102(e)日期1992年4月7日PCT 1990年10月19日提交了包含氨基酸亚序列Arg-Arg-Lys-Trp-Gln的新型合成多肽由本发明提供。 还提供了使用这种多肽,含有这种亚序列的其它已知多肽和多种酸性或碱性多肽和蛋白质作为γ干扰素与其细胞受体结合的抑制剂的方法。 本发明的方法可能适用于治疗被认为是由γ干扰素介导的病理状态,例如自身免疫性疾病。